

YEAR IN REVIEW 2025



The Global Alzheimer's Platform Foundation® (GAP) is celebrating our tenth year pursuing our mission to speed the discovery of Alzheimer's and Parkinson's disease therapies by shortening the duration, reducing the cost, and improving access and the effectiveness of clinical trials.

GAP's expanding footprint also includes our first GAP-Owned and Operated Site (GOOS), **Axiom Brain Health**, and the foundation of a future **Las Vegas research site** in partnership with the University of Nevada, Las Vegas (UNLV), focused on cutting-edge science and innovation.

Flagship Programs Driving Impact

GAP's Participant Services (GPS)

The GAP Participant Services (GPS) program is the premier "boots-on-the-ground" field team supporting GAP-Net sites with Alzheimer's and Parkinson's trial recruitment and site optimization. This team of experienced research professionals delivers memory screening and education events, provider outreach, digital and earned media strategies, and hands-on site support to streamline workflows and maximize screening and randomization success.

514 visits with GAP-Net sites

165 community outreach events

2,600+ referrals

1,200+ participants screened

Inclusive Research Initiative (IRI)

GAP's Inclusive Research Initiative (IRI) program expands clinical research participation among racial and ethnic groups historically understudied in Alzheimer's and Parkinson's trials by meeting them where they are—including African American/Black, Latino/Hispanic, Asian American, Pacific Islander, Native American/Indigenous communities, rural communities, LGBTQIA+ individuals, and people impacted by socioeconomic and educational disparities—to expand access and participation in research.

330 visits with GAP-Net sites

2025 Study Success highlights

53% of people screened were from understudied populations

31% of people randomized were from understudied populations

77% of people screened in pre-screener study were from understudied populations

Mobile Research Unit (MRU): Taking Health on the Road



Launched with support from Roche's TRAVELLER Study, from when we hit the road in earnest in August through the end of the year, GAP deployed two Mobile Research Units—**THOR East and THOR West**—to lower barriers to participation across underserved and understudied communities.

13+ GAP-Net Site collaborations

70 community events

5,900+ people attended community events and health fairs

819 people referred to clinical trials

349 people completed memory assessments

160 study screens (including **84 USP screens**)

The MRU delivers brain health education, free memory screening, and direct access to clinical trial opportunities, meeting people in their own communities.

This data represents events from August through December, 2025.

Alzheimer's and Dementia Diagnostics Diagnostics & Biomarker Science

GAP's Bio-Hermes study is producing some of the most influential Alzheimer's biomarker data worldwide.

Bio-Hermes-001

After the study closed in 2024, the data has brought substantial value that impacts the field

- 2025 played a **principal role** in supporting **FDA clearance of the first blood test** to diagnose Alzheimer's: Fujirebio Lumipulse G pTau217/-Amyloid 1-42 Plasma Ratio IVD
- Dataset made publicly available in 2025; **101 research teams requested access within months**
- Enabled major scientific advances published in 4 papers including **Nature Aging**, identifying blood-based proteomic signatures related to amyloid pathology, immune function, and metabolic processes

Bio-Hermes-002

- Ongoing platform study comparing **blood-based and digital biomarkers to amyloid and tau PET scans** across a deliberately diverse cohort launched with the first participant screening on September 30, 2024
- Unprecedented commitment to ensuring **25% participation from people from understudied communities**
- Partners include diagnostic, pharma, digital, and philanthropic partners
- Over 5,000 fluid markers (including genomics and proteomics) and 100 digital markers

Partners



Marketing Spotlight

GAP had a presence at more than **23** conferences/events attended. GAP hosted one in-person conference with almost **300 attendees** and one virtual IRI conference with **184 attendees**.

30+ Paper publications. **30K** Website Visitors up **57%** from 2024. **702 K** Social media impressions

1.6K New followers. **2.5K** Total posts across all social media channels. **1.6 K+** Earned media stories with **838.8M** impressions

Industry Partners



Our Impact

From pioneering diversity-driven biomarker research to mobilizing clinical trial access for communities nationwide, GAP is transforming the future of Alzheimer's and Parkinson's disease research. Our progress is only possible because of our sites, our partners, and our **Citizen Scientists**—the volunteers who make clinical breakthroughs possible.

To learn more contact info@globalalzplatform.org